A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome

Current Medical Research and Opinion

Volumn 24, Issue 8, 2008, Pages 2173-2179

  Speakman, Mark ^a   Khullar, Vik ^b   Mundy, Anthony ^c   Odeyemi, Isaac ^d   Bolodeoku, John ^d  

^a MUSGROVE PARK HOSPITAL   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d ASTELLAS PHARMA EUROPE LTD   (United Kingdom)

Author keywords

Antimuscarinic; Cost effectiveness analysis; Cost utility analysis; Markov model; Overactive bladder syndrome; Solifenacin; Tolterodine

Indexed keywords

SOLIFENACIN; TOLTERODINE;

CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HIDDEN MARKOV MODEL; HUMAN; MAJOR CLINICAL STUDY; MICTURITION; NATIONAL HEALTH SERVICE; OVERACTIVE BLADDER; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSITIVITY ANALYSIS; URINE INCONTINENCE;

EID: 50149099172     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802234829     Document Type: Review

References (18)

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 20021;21:167-78
2. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. Br J Urol Int 2001; 87:760-6
3. Booth C, Pascoe D. A comparison of newer drug treatments for urinary incontinence. Hospital Pharmacist 2002;9:69-75
4. Kreder K, Mayne C, Jonas U. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol 2002;41:588-95
5. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70
6. Kobelt G, Jonsson L, Mattiasson A. Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model. Neurourol Urodyn 1998;17:599-611
7. Johannesson M, O'Conor RM, Kobelt-Nguyen G, et al. Willingness to pay for reduced incontinence symptoms. Br J Urol 1997;80:557-62
8. Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. Br J Urol Int 2004; 93:303-10
9. Haab F, Cardozo L, Chapple C, et al. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005; 47:376-84
10. Kobelt G. Economic considerations and outcome measurement in urge incontinence. Urology 1997;50(Suppl 6A): 100-7 discussion 108-10
11. O'Brien BJ, Goeree R, Bernard L, et al. Cost-effectiveness of tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: a Canadian perspective. Clin Ther 2001;23:2038-49
12. Netten A, Curtis L. Hospital & community health services (HCHS) pay and prices index in unit costs of health and social care. Canterbury (UK): PSSRU Personal Social Services Research Unit; 2004
13. Netten A, Curtis L. Unit costs of health and social care. Canterbury (UK): PSSRU Personal Social Services Research Unit; 2005
14. The Continence Foundation. Making the case of investment in an integrated continence service; 2000
15. IMS Health. MIDAS, MAT, 2007
16. Chapple CR, Artibani W, Cardozo LD, et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. Br J Urol Int 2005;95:335-40
17. Department of Health. Prescription cost analysis 1999 http://www.dh.gov.uk/en/Publicationsandstatistics/Statistics/ StatisticalWorkAreas/Statisticalhealthcare/ DH-4015574?IdcService=GET_FILE&dID=28768&Rendition=Web
18. Department of Health prescription cost analysis 2006. http://www.ic.nbs.uk/webfiles/publications/pca2006/PCA_2006.pdf